Homepage
Author:
Cadrenal Therapeutics Inc.
Posted Date:
June 3, 2026
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Cadrenal Therapeutics Inc.
June 3, 2026
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Cadrenal Therapeutics Inc.
May 19, 2026
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Cadrenal Therapeutics Inc.
May 7, 2026
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
Cadrenal Therapeutics Inc.
April 30, 2026
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Cadrenal Therapeutics Inc.
March 31, 2026
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
Cadrenal Therapeutics Inc.
March 12, 2026
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
Cadrenal Therapeutics Inc.
March 2, 2026
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
Cadrenal Therapeutics Inc.
February 24, 2026
